Spectrophotometric investigation of the chemical compatibility of the anticancer drugs irinotecan-HCl and epirubicin-HCl in the same infusion solution

Cancer Chemotherapy and Pharmacology

Volumn 56, Issue 5, 2005, Pages 529-534

  Ozdemir, Filiz Arioz ^a   Anilanmert, Beril ^a   Pekin, Mursit ^a  

^a MARMARA UNIVERSITY   (Turkey)

Author keywords

Chemical compatibility; Epirubicin; Interaction; Irinotecan; Spectrophotometry; Visual compatibility

Indexed keywords

EPIRUBICIN; IRINOTECAN;

ARTICLE; CHEMICAL INTERACTION; COLOR; DRUG INFUSION; PH; PRECIPITATION; PRIORITY JOURNAL; SPECTROPHOTOMETRY; STANDARD;

ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; DRUG COMBINATIONS; DRUG INCOMPATIBILITY; DRUG STABILITY; EPIRUBICIN; INFUSIONS, INTRAVENOUS; PHARMACEUTICAL SOLUTIONS; SPECTROPHOTOMETRY, ULTRAVIOLET;

EID: 27644497123     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-004-0990-z     Document Type: Article

References (19)

1. Chen X, Oza AM, Kusenda Z, et al (2003) Phase I study of cisplatin, irinotecan and epirubicin administered every two weeks in patients with advanced solid tumours. Br J Cancer 89(4):617-624
2. Chollet DF, Goumaz L, Renard A, et al (1998) Simultaneous determination of the lactone and carboxylate forms of the camptothecin derivative CPT-11 and its metabolite SN-38 in plasma by high performance liquid chromatography. J Chromatogr B 718:163-175
3. Cohen MH, Johnston-Early A, Hood MA, et al (1985) Drug precipitation within IV tubing: a potential hazard of chemotherapy administration. Cancer Treat Rep 69:1325-1326
4. Ellence (1999) Epirubicin hydrochloride injection, revised package insert. Pharmacia & Upjohn, Perth
5. Hwang JJ, Marshall JL, Rizvi N (2003) Combined inhibition of topoisomerases: a phase 1 study of irinotecan and epirubicin. Oncology 17 [Suppl 5]:S46-S51
6. Lacy LF, Armstrong LL, Goldman MP (2002/2003) Drug information handbook with international index. Lexi-comp, Hudson, Cleveland, pp 472-474
7. Living Proof (2000) Camptosar, Pharmacia & Upjohn, Yakult, Daiichi
8. Marshall JL, Baidas S, Rizvi N (2002) Phase I trial of irinotecan and epirubicin in advanced cancer. Preliminary report. Oncology New York (Huntingt) 16:17-19
9. McRae MP, King JC (1976) Compatibility of antineoplastic, antibiotic and corticosteroid drugs in intravenous admixtures. Am J Hosp Pharm 33:1010-1013
10. Parfitt K, Sweetman SC, Blake PS, Parsons AV (1999) The complete drug reference, 32nd edn. Pharmaceutical Press, London, p 543
11. Pizzolato JF, Saltz LB (2003) The camptothecins. Lancet 361:2235-2242
12. Radford JA, Margison JM, Swindell R, Mad MJ, Wilkinson PM, Thatcher N (1991) The stability of ifosfamide in aqueous solution and its suitability for continuous 7-day infusion by ambulatory pump. J Cancer Res Clin Oncol 117 [Suppl IV]:S151-S156
13. Rothenberg ML, Blanke CD (1999) Topoisomerase 1 inhibitors in the treatment of colorectal cancer. Colorectal cancer: past accomplishments and future directions II. Semin Oncol 26:632-639
14. Trissel LA, Parks NPT, Santiago NM (1991) Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection. Am J Hosp Pharm 48:2186-2189
15. USP (1997) Drug information for the health care professional, vol I. 17th edn. United States Pharmacopeia Convention, Rockville, MD, pp 3040-3050
16. Weiss RB (1992) The anthracyclines: will we ever find a better doxorubicin? Semin Oncol 19(6):670-686
17. Wilkinson K (2001) Irinotecan hydrochloride. Clin J Oncol Nurs 5(4):179-180, 184
18. Williams DA, Lokich JA (1994) Review of the stability and compatibility of antineoplastic drugs for multiple-drug infusions. Cancer Chemother Pharmacol 31:171-181
19. Wood MJ, Irwin WJ, Scott DK (1990) Stability of daunorubicin, doxorubicin and epirubicin in plastic syringes and minibags. J Clin Pharm Ther 15:279-289